Selected research
Market Structure
Global Liposomal-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Liposomal-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Liposomal-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Liposomal-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Liposomal-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Liposomal-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Liposomal-based Drug include Takeda, Teva, Sun Pharmaceutical, Johnson & Johnson, Chiesi Farmaceutici, Gilead Sciences, Zydus Cadila, TTY Biopharma and Sayre Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Liposomal-based Drug market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Liposomal-based Drug and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Liposomal-based Drug revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Liposomal-based Drug market size, projected growth trends, production technologies, key applications, and end-use industries.
Liposomal-based Drug Segment by Company
Takeda
Teva
Sun Pharmaceutical
Johnson & Johnson
Chiesi Farmaceutici
Gilead Sciences
Zydus Cadila
TTY Biopharma
Sayre Therapeutics
Pacira
Luye Pharma
Leadiant Biosciences
Kinyond
Jazz
Ipsen
Fudan-Zhangjiang
CSPC
Bausch Health
Alnylam
Acrotech Biopharma
Liposomal-based Drug Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Liposomal-based Drug Segment by Application
Hospital
Retail Pharmacy
Other
Liposomal-based Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Liposomal-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Liposomal-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Liposomal-based Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Liposomal-based Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Liposomal-based Drug industry.
Chapter 3: Detailed analysis of Liposomal-based Drug companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Liposomal-based Drugrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Liposomes Drugs
- Lipid Nanoparticle Drugs
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Takeda
- Teva
- Sun Pharmaceutical
- Johnson & Johnson
- Chiesi Farmaceutici
- Gilead Sciences
- Zydus Cadila
- TTY Biopharma
- Sayre Therapeutics
- Pacira
- Luye Pharma
- Leadiant Biosciences
- Kinyond
- Jazz
- Ipsen
- Fudan-Zhangjiang
- CSPC
- Bausch Health
- Alnylam
- Acrotech Biopharma
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Liposomal-based Drug Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Liposomes Drugs
- 1.2.3 Lipid Nanoparticle Drugs
- 1.3 Market Analysis by Application
- 1.3.1 Global Liposomal-based Drug Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Retail Pharmacy
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Liposomal-based Drug Growth Trends by Region
- 1.5.1 Global Liposomal-based Drug Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Liposomal-based Drug Market Size by Region (2021-2026)
- 1.5.3 Liposomal-based Drug Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Liposomal-based Drug Market Dynamics
- 2.1 Liposomal-based Drug Industry Trends
- 2.2 Liposomal-based Drug Industry Drivers
- 2.3 Liposomal-based Drug Industry Opportunities and Challenges
- 2.4 Liposomal-based Drug Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Liposomal-based Drug Revenue by Company (2021-2026)
- 3.2 Global Liposomal-based Drug Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Liposomal-based Drug Key Company Head office and Area Served
- 3.4 Global Liposomal-based Drug Company, Product Type & Application
- 3.5 Global Liposomal-based Drug Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Liposomal-based Drug Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Liposomal-based Drug Players Market Share by Revenue in 2025
- 3.6.3 2025 Liposomal-based Drug Tier 1, Tier 2, and Tier 3
4 Liposomal-based Drug Market by Type
- 4.1 Global Liposomal-based Drug Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Liposomal-based Drug Market Size by Type (2021-2032)
- 4.3 Global Liposomal-based Drug Market Size Share by Type (2021-2032)
5 Liposomal-based Drug Market by Application
- 5.1 Global Liposomal-based Drug Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Liposomal-based Drug Market Size by Application (2021-2032)
- 5.3 Global Liposomal-based Drug Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Takeda
- 6.1.1 Takeda Company Information
- 6.1.2 Takeda Business Overview
- 6.1.3 Takeda Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Takeda Liposomal-based Drug Product Portfolio
- 6.1.5 Takeda Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Teva Liposomal-based Drug Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sun Pharmaceutical
- 6.3.1 Sun Pharmaceutical Company Information
- 6.3.2 Sun Pharmaceutical Business Overview
- 6.3.3 Sun Pharmaceutical Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sun Pharmaceutical Liposomal-based Drug Product Portfolio
- 6.3.5 Sun Pharmaceutical Recent Developments
- 6.4 Johnson & Johnson
- 6.4.1 Johnson & Johnson Company Information
- 6.4.2 Johnson & Johnson Business Overview
- 6.4.3 Johnson & Johnson Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Johnson & Johnson Liposomal-based Drug Product Portfolio
- 6.4.5 Johnson & Johnson Recent Developments
- 6.5 Chiesi Farmaceutici
- 6.5.1 Chiesi Farmaceutici Company Information
- 6.5.2 Chiesi Farmaceutici Business Overview
- 6.5.3 Chiesi Farmaceutici Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Chiesi Farmaceutici Liposomal-based Drug Product Portfolio
- 6.5.5 Chiesi Farmaceutici Recent Developments
- 6.6 Gilead Sciences
- 6.6.1 Gilead Sciences Company Information
- 6.6.2 Gilead Sciences Business Overview
- 6.6.3 Gilead Sciences Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Gilead Sciences Liposomal-based Drug Product Portfolio
- 6.6.5 Gilead Sciences Recent Developments
- 6.7 Zydus Cadila
- 6.7.1 Zydus Cadila Company Information
- 6.7.2 Zydus Cadila Business Overview
- 6.7.3 Zydus Cadila Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Zydus Cadila Liposomal-based Drug Product Portfolio
- 6.7.5 Zydus Cadila Recent Developments
- 6.8 TTY Biopharma
- 6.8.1 TTY Biopharma Company Information
- 6.8.2 TTY Biopharma Business Overview
- 6.8.3 TTY Biopharma Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 TTY Biopharma Liposomal-based Drug Product Portfolio
- 6.8.5 TTY Biopharma Recent Developments
- 6.9 Sayre Therapeutics
- 6.9.1 Sayre Therapeutics Company Information
- 6.9.2 Sayre Therapeutics Business Overview
- 6.9.3 Sayre Therapeutics Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Sayre Therapeutics Liposomal-based Drug Product Portfolio
- 6.9.5 Sayre Therapeutics Recent Developments
- 6.10 Pacira
- 6.10.1 Pacira Company Information
- 6.10.2 Pacira Business Overview
- 6.10.3 Pacira Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Pacira Liposomal-based Drug Product Portfolio
- 6.10.5 Pacira Recent Developments
- 6.11 Luye Pharma
- 6.11.1 Luye Pharma Company Information
- 6.11.2 Luye Pharma Business Overview
- 6.11.3 Luye Pharma Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 Luye Pharma Liposomal-based Drug Product Portfolio
- 6.11.5 Luye Pharma Recent Developments
- 6.12 Leadiant Biosciences
- 6.12.1 Leadiant Biosciences Company Information
- 6.12.2 Leadiant Biosciences Business Overview
- 6.12.3 Leadiant Biosciences Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 Leadiant Biosciences Liposomal-based Drug Product Portfolio
- 6.12.5 Leadiant Biosciences Recent Developments
- 6.13 Kinyond
- 6.13.1 Kinyond Company Information
- 6.13.2 Kinyond Business Overview
- 6.13.3 Kinyond Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Kinyond Liposomal-based Drug Product Portfolio
- 6.13.5 Kinyond Recent Developments
- 6.14 Jazz
- 6.14.1 Jazz Company Information
- 6.14.2 Jazz Business Overview
- 6.14.3 Jazz Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Jazz Liposomal-based Drug Product Portfolio
- 6.14.5 Jazz Recent Developments
- 6.15 Ipsen
- 6.15.1 Ipsen Company Information
- 6.15.2 Ipsen Business Overview
- 6.15.3 Ipsen Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 Ipsen Liposomal-based Drug Product Portfolio
- 6.15.5 Ipsen Recent Developments
- 6.16 Fudan-Zhangjiang
- 6.16.1 Fudan-Zhangjiang Company Information
- 6.16.2 Fudan-Zhangjiang Business Overview
- 6.16.3 Fudan-Zhangjiang Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 Fudan-Zhangjiang Liposomal-based Drug Product Portfolio
- 6.16.5 Fudan-Zhangjiang Recent Developments
- 6.17 CSPC
- 6.17.1 CSPC Company Information
- 6.17.2 CSPC Business Overview
- 6.17.3 CSPC Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 CSPC Liposomal-based Drug Product Portfolio
- 6.17.5 CSPC Recent Developments
- 6.18 Bausch Health
- 6.18.1 Bausch Health Company Information
- 6.18.2 Bausch Health Business Overview
- 6.18.3 Bausch Health Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Bausch Health Liposomal-based Drug Product Portfolio
- 6.18.5 Bausch Health Recent Developments
- 6.19 Alnylam
- 6.19.1 Alnylam Company Information
- 6.19.2 Alnylam Business Overview
- 6.19.3 Alnylam Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.19.4 Alnylam Liposomal-based Drug Product Portfolio
- 6.19.5 Alnylam Recent Developments
- 6.20 Acrotech Biopharma
- 6.20.1 Acrotech Biopharma Company Information
- 6.20.2 Acrotech Biopharma Business Overview
- 6.20.3 Acrotech Biopharma Liposomal-based Drug Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.20.4 Acrotech Biopharma Liposomal-based Drug Product Portfolio
- 6.20.5 Acrotech Biopharma Recent Developments
7 North America
- 7.1 North America Liposomal-based Drug Market Size (2021-2032)
- 7.2 North America Liposomal-based Drug Market Size by Type
- 7.2.1 North America Liposomal-based Drug Market Size by Type (2021-2026)
- 7.2.2 North America Liposomal-based Drug Market Size by Type (2027-2032)
- 7.2.3 North America Liposomal-based Drug Market Share by Type (2021-2032)
- 7.3 North America Liposomal-based Drug Market Size by Application
- 7.3.1 North America Liposomal-based Drug Market Size by Application (2021-2026)
- 7.3.2 North America Liposomal-based Drug Market Size by Application (2027-2032)
- 7.3.3 North America Liposomal-based Drug Market Share by Application (2021-2032)
- 7.4 North America Liposomal-based Drug Market Size by Country
- 7.4.1 North America Liposomal-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Liposomal-based Drug Market Size by Country (2021-2026)
- 7.4.3 North America Liposomal-based Drug Market Size by Country (2027-2032)
- 7.4.4 North America Liposomal-based Drug Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Liposomal-based Drug Market Size (2021-2032)
- 8.2 Europe Liposomal-based Drug Market Size by Type
- 8.2.1 Europe Liposomal-based Drug Market Size by Type (2021-2026)
- 8.2.2 Europe Liposomal-based Drug Market Size by Type (2027-2032)
- 8.2.3 Europe Liposomal-based Drug Market Share by Type (2021-2032)
- 8.3 Europe Liposomal-based Drug Market Size by Application
- 8.3.1 Europe Liposomal-based Drug Market Size by Application (2021-2026)
- 8.3.2 Europe Liposomal-based Drug Market Size by Application (2027-2032)
- 8.3.3 Europe Liposomal-based Drug Market Share by Application (2021-2032)
- 8.4 Europe Liposomal-based Drug Market Size by Country
- 8.4.1 Europe Liposomal-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Liposomal-based Drug Market Size by Country (2021-2026)
- 8.4.3 Europe Liposomal-based Drug Market Size by Country (2027-2032)
- 8.4.4 Europe Liposomal-based Drug Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Liposomal-based Drug Market Size (2021-2032)
- 9.2 China Liposomal-based Drug Market Size by Type
- 9.2.1 China Liposomal-based Drug Market Size by Type (2021-2026)
- 9.2.2 China Liposomal-based Drug Market Size by Type (2027-2032)
- 9.2.3 China Liposomal-based Drug Market Share by Type (2021-2032)
- 9.3 China Liposomal-based Drug Market Size by Application
- 9.3.1 China Liposomal-based Drug Market Size by Application (2021-2026)
- 9.3.2 China Liposomal-based Drug Market Size by Application (2027-2032)
- 9.3.3 China Liposomal-based Drug Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Liposomal-based Drug Market Size (2021-2032)
- 10.2 Asia Liposomal-based Drug Market Size by Type
- 10.2.1 Asia Liposomal-based Drug Market Size by Type (2021-2026)
- 10.2.2 Asia Liposomal-based Drug Market Size by Type (2027-2032)
- 10.2.3 Asia Liposomal-based Drug Market Share by Type (2021-2032)
- 10.3 Asia Liposomal-based Drug Market Size by Application
- 10.3.1 Asia Liposomal-based Drug Market Size by Application (2021-2026)
- 10.3.2 Asia Liposomal-based Drug Market Size by Application (2027-2032)
- 10.3.3 Asia Liposomal-based Drug Market Share by Application (2021-2032)
- 10.4 Asia Liposomal-based Drug Market Size by Country
- 10.4.1 Asia Liposomal-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Liposomal-based Drug Market Size by Country (2021-2026)
- 10.4.3 Asia Liposomal-based Drug Market Size by Country (2027-2032)
- 10.4.4 Asia Liposomal-based Drug Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Liposomal-based Drug Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Liposomal-based Drug Market Size by Type
- 11.2.1 South America, Middle East & Africa Liposomal-based Drug Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Liposomal-based Drug Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Liposomal-based Drug Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Liposomal-based Drug Market Size by Application
- 11.3.1 South America, Middle East & Africa Liposomal-based Drug Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Liposomal-based Drug Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Liposomal-based Drug Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Liposomal-based Drug Market Size by Country
- 11.4.1 South America, Middle East & Africa Liposomal-based Drug Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Liposomal-based Drug Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Liposomal-based Drug Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Liposomal-based Drug Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst